


Drug Stability

Principles and Practices



Jens T. Carstensen

Drug Stability

Principles and Practices

JENS T. CARSTENSEN

Univeristy of Wisconsin—Madison
Madison, Wisconsin



Marcel Dekker, Inc.

New York and Basel

Library of Congress Cataloging-in-Publication Data

Carstensen, Jens Thuro.

Drug stability : principles and practices / Jens T. Carstensen.
p. cm. -- (Drugs and the pharmaceutical sciences : v.43)

Includes bibliographical references.

ISBN 0-8247-8285-2 (alk. paper)

1. Drug stability. I. Title. II. Series.

RS424.C37 1990

89-71534

615' .18--dc20

CIP

This book is printed on acid-free paper.

Copyright © 1990 by MARCEL DEKKER, INC. All Rights Reserved

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.

270 Madison Avenue, New York, New York 10016

Current printing (last digit):

10 9 8 7 6 5 4 3 2

PRINTED IN THE UNITED STATES OF AMERICA

Drug Stability

DRUGS AND THE PHARMACEUTICAL SCIENCES

A Series of Textbooks and Monographs

Edited by

James Swarbrick

School of Pharmacy

University of North Carolina

Chapel Hill, North Carolina

- Volume 1. PHARMACOKINETICS, *Milo Gibaldi and Donald Perrier*
(out of print)
- Volume 2. GOOD MANUFACTURING PRACTICES FOR
PHARMACEUTICALS: A PLAN FOR TOTAL QUALITY
CONTROL, *Sidney H. Willig, Murray M. Tuckerman, and*
William S. Hitchings IV (out of print)
- Volume 3. MICROENCAPSULATION, *edited by J. R. Nixon*
- Volume 4. DRUG METABOLISM: CHEMICAL AND BIOCHEMICAL
ASPECTS, *Bernard Testa and Peter Jenner*
- Volume 5. NEW DRUGS: DISCOVERY AND DEVELOPMENT,
edited by Alan A. Rubin
- Volume 6. SUSTAINED AND CONTROLLED RELEASE DRUG DELIVERY
SYSTEMS, *edited by Joseph R. Robinson*
- Volume 7. MODERN PHARMACEUTICS, *edited by Gilbert S.*
Banker and Christopher T. Rhodes
- Volume 8. PRESCRIPTION DRUGS IN SHORT SUPPLY: CASE
HISTORIES, *Michael A. Schwartz*
- Volume 9. ACTIVATED CHARCOAL: ANTIDOTAL AND OTHER
MEDICAL USES, *David O. Cooney*
- Volume 10. CONCEPTS IN DRUG METABOLISM (in two parts), *edited*
by Peter Jenner and Bernard Testa
- Volume 11. PHARMACEUTICAL ANALYSIS: MODERN METHODS
(in two parts), *edited by James W. Munson*
- Volume 12. TECHNIQUES OF SOLUBILIZATION OF DRUGS,
edited by Samuel H. Yalkowsky

- Volume 13. ORPHAN DRUGS, *edited by Fred E. Karch*
- Volume 14. NOVEL DRUG DELIVERY SYSTEMS: FUNDAMENTALS, DEVELOPMENTAL CONCEPTS, BIOMEDICAL ASSESSMENTS, *Yie W. Chien*
- Volume 15. PHARMACOKINETICS, Second Edition, Revised and Expanded, *Milo Gibaldi and Donald Perrier*
- Volume 16. GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICALS: A PLAN FOR TOTAL QUALITY CONTROL, Second Edition, Revised and Expanded, *Sidney H. Willig, Murray M. Tuckerman, and William S. Hitchings IV*
- Volume 17. FORMULATION OF VETERINARY DOSAGE FORMS, *edited by Jack Blodinger*
- Volume 18. DERMATOLOGICAL FORMULATIONS: PERCUTANEOUS ABSORPTION, *Brian W. Barry*
- Volume 19. THE CLINICAL RESEARCH PROCESS IN THE PHARMACEUTICAL INDUSTRY, *edited by Gary M. Matoren*
- Volume 20. MICROENCAPSULATION AND RELATED DRUG PROCESSES, *Patrick B. Deasy*
- Volume 21. DRUGS AND NUTRIENTS: THE INTERACTIVE EFFECTS, *edited by Daphne A. Roe and T. Colin Campbell*
- Volume 22. BIOTECHNOLOGY OF INDUSTRIAL ANTIBIOTICS, *Erick J. Vandamme*
- Volume 23. PHARMACEUTICAL PROCESS VALIDATION, *edited by Bernard T. Loftus and Robert A. Nash*
- Volume 24. ANTICANCER AND INTERFERON AGENTS: SYNTHESIS AND PROPERTIES, *edited by Raphael M. Ottenbrite and George B. Butler*
- Volume 25. PHARMACEUTICAL STATISTICS: PRACTICAL AND CLINICAL APPLICATIONS, *Sanford Bolton*
- Volume 26. DRUG DYNAMICS FOR ANALYTICAL, CLINICAL, AND BIOLOGICAL CHEMISTS, *Benjamin J. Gudzinowicz, Burrows T. Younkin, Jr., and Michael J. Gudzinowicz*

- Volume 27. MODERN ANALYSIS OF ANTIBIOTICS, *edited by Adorjan Aszalos*
- Volume 28. SOLUBILITY AND RELATED PROPERTIES, *Kenneth C. James*
- Volume 29. CONTROLLED DRUG DELIVERY: FUNDAMENTALS AND APPLICATIONS, Second Edition, Revised and Expanded, *edited by Joseph R. Robinson and Vincent H. L. Lee*
- Volume 30. NEW DRUG APPROVAL PROCESS: CLINICAL AND REGULATORY MANAGEMENT, *edited by Richard A. Guarino*
- Volume 31. TRANSDERMAL CONTROLLED SYSTEMIC MEDICATIONS, *edited by Yie W. Chien*
- Volume 32. DRUG DELIVERY DEVICES: FUNDAMENTALS AND APPLICATIONS, *edited by Praveen Tyle*
- Volume 33. PHARMACOKINETICS: REGULATORY • INDUSTRIAL • ACADEMIC PERSPECTIVES, *edited by Peter G. Welling and Francis L. S. Tse*
- Volume 34. CLINICAL DRUG TRIALS AND TRIBULATIONS, *edited by Allen E. Cato*
- Volume 35. TRANSDERMAL DRUG DELIVERY: DEVELOPMENTAL ISSUES AND RESEARCH INITIATIVES, *edited by Jonathan Hadgraft and Richard H. Guy*
- Volume 36. AQUEOUS POLYMERIC COATINGS FOR PHARMACEUTICAL DOSAGE FORMS, *edited by James W. McGinity*
- Volume 37. PHARMACEUTICAL PELLETIZATION TECHNOLOGY, *edited by Isaac Ghebre-Sellassie*
- Volume 38. GOOD LABORATORY PRACTICE REGULATIONS, *edited by Allen F. Hirsch*
- Volume 39. NASAL SYSTEMIC DRUG DELIVERY, *Yie W. Chien, Kenneth S. E. Su, and Shyi-Feu Chang*
- Volume 40. MODERN PHARMACEUTICS, Second Edition, Revised and Expanded, *edited by Gilbert S. Banker and Christopher T. Rhodes*
- Volume 41. SPECIALIZED DRUG DELIVERY SYSTEMS: MANUFACTURING AND PRODUCTION TECHNOLOGY, *edited by Praveen Tyle*
- Volume 42. TOPICAL DRUG DELIVERY FORMULATIONS, *edited by David W. Osborne and Anton H. Amann*

Volume 43. DRUG STABILITY: PRINCIPLES AND PRACTICES,
Jens T. Carstensen

Additional Volumes in Preparation

PHARMACEUTICAL STATISTICS: PRACTICAL AND CLINI-
CAL APPLICATIONS, Second Edition, Revised and Expanded,
Sanford Bolton

To Dorothy Dolfini
for her inspiration, support, and love

Preface

I have been engaged in one or another phase of stability testing or theory for most of my professional life. Beyond the purely organizational subdivisions of stability and its association with the science of kinetics there exist fascinating aspects of the subject from a work point of view.

A stability problem is never simple. It is, as Dr. E. G. Garrett of the University of Florida says, never a "Saturday afternoon experiment." No two problems are alike. Once a drug substance is manipulated into a dosage form, it interacts with the excipients in an individual manner that always presents challenge, variety, and constant search for knowledge. At the time a product is ready for new drug application (NDA), there is a storehouse of unique knowledge, which frequently leads to one or more publications. The dissemination of this knowledge was not always a timely or smooth process. It was not until the last decade that companies in general began to look kindly on publication efforts by their applied scientists. Fortunately, stability efforts now find their way to the journals where they can be shared for a better general understanding of common stability problems.

This book is written primarily with the stability scientist in mind. Although over 500 references are cited, it is not merely a reference text. The references were selected to illustrate the examples of the principles that I have presented, not to serve as an exhaustive bibliography.

Because the book also presents the underlying theory of stability testing, there is a fair amount of mathematical machinery brought into play, but this should not discourage the mathematically uninitiated. The chapters, especially the later ones, all have very applied aspects and can be read by skipping the math. The reason for employing the

mathematics, the modeling, and the mechanistic aspects is to provide a well-rounded publication which will serve as a reference model for models and mechanistics of stability theory. Colleagues in this field may wish to use the book as a text for courses in stability.

I owe special thanks to Dr. Charles Kumkumian of the United States Food and Drug Administration, Professor Christopher Rhodes of the University of Rhode Island, Dr. Rohit Kothari and Ms. Dorothy Dolfini of Marion Labs, Dr. Robert Cohn and Dr. D. Wadke of Bristol-Squibb, Corp., Dr. G. K. Mooney of Lederle Labs, and Drs. Paul Turi, Bert Brown, and Claire Bosco of Sandoz for valuable technical assistance, information, and encouragement.

Finally, I owe special thanks to the scientists who will read this text and enjoy it.

Jens T. Carstensen

Contents

<i>Preface</i>	v
1. Overview	1
1. Historical Background	2
2. Definitions of Pharmaceutical Stability	4
3. Some Official Definitions	5
4. Chemical Stability Versus Kinetics	10
5. Comments on Physical Plant	11
6. Sequence of Events	11
References	14
2. Solution Kinetics	15
1. The Order of a Reaction	17
2. The Zero-Order Reaction	18
3. First-Order Reactions	18
4. First-Order Reactions with More Than One End Product	22
5. Temperature Effects	29
6. Nonisothermal Kinetics	34
7. Second-Order Reactions	36
8. Pseudo-First-Order Reactions	44
9. Kinetic pH Profiles	46
10. Effect of Solvent	79
11. Kinetic Salt Effect	80
12. Oxidative Reactions	83

13. Catalysis	94
14. Complexation	96
15. Photolysis	99
References	101
3. Disperse and Aggregated Systems	109
1. Micellar Systems	109
2. Emulsions	113
3. Liposomes	115
4. Suspensions	118
5. Antacid Suspensions	125
6. Microcapsule Suspensions	126
References	126
4. Solid-State Stability	129
1. Decomposition Modes of Pure Solids	130
2. The Solid to Solid + Gas Reaction	130
3. Temperature Effect on Prout-Tompkins Constants	136
4. The Solid to Liquid + Gas Reaction	137
5. Topochemical Reactions	145
6. Interactions	147
7. Incompatibility Prevention Techniques	153
8. Diffusion-Controlled Interactions	156
9. Interactions Involving a Liquid Phase	157
10. Cases of Interaction of a Liquid with a Poorly Soluble Drug	162
11. Reactions via the Gas Phase	163
References	163
5. Effect of Moisture on the Stability of Solid Dosage Forms	165
1. The State of Moisture in Solid Dosage Forms	166
2. Equilibrium Moisture Content	166
3. Moisture Exchange Between Dosage Form Ingredients	172
4. Decomposition with Nondepleting Moisture	174
5. Specific Excipients	191
References	204

6. Statistical Aspects	209
1. Some Definitions of Pharmaceutical Use	211
2. Sampling	213
3. Some Often-Used Statistical Tests	217
4. Analytical Methods	222
5. Orders of Reactions	225
6. The "Best" Line	226
7. Expiration Periods	233
8. Very Stable Products	240
9. Pooled Data	241
10. Equivalence Testing	247
11. Interval Selection	250
12. Changing Content Uniformity: Weighted Least Squares	251
13. Plateauing	252
14. Statistics of Arrhenius Plotting	253
References	260
 7. Preformulation	 263
1. Solubility	264
2. pK Determinations	277
3. Kinetics	283
4. Hygroscopicity	284
5. Compatibility	288
6. Melting-Point Diagrams	289
7. Other Preformulation Aspects	299
References	299
 8. Pharmaceutical Packaging	 301
1. Glass	302
2. Lag Times	305
3. Moisture Permeation into Empty Bottles	308
4. Peppas Kinetics	314
5. Stability of Moisture-Sensitive Substances in Plastic Containers	323
6. Dessicant Bags	325
7. Liquids in Plastic Containers (Leaching Kinetics)	329
8. The Container Closure	333
9. Guidelines	334
References	335

9. Physical Testing	337
1. Physical Stability of Solutions	339
2. Parenteral Solutions	341
3. Disperse Systems	347
4. Suspensions	347
5. Emulsions	354
6. Aerosols	365
7. Powders	369
8. Tablets	371
9. Sustained Release Products	394
10. Coated Tablets	399
11. Hard- and Soft-Shell Capsules	402
12. Microcapsules	403
13. Light Sensitivity Testing	404
14. Diagnostic Papers	406
15. Expiration Periods	406
References	407
10. Modus Operandi for a Stability Program	411
1. Goals of the Stability Program	412
2. Organization	413
3. Preformulation Organization	413
4. Pull Times	414
5. Preclinical Formulation	419
6. Clinical Formulation	420
7. Late Clinical and First Pilot Batches	422
8. Marketed Product Stability	422
9. Storage Requirements	423
10. Stability Monitoring	426
11. Microbial Testing	430
12. Storage Intervals	431
13. Logistics	432
14. Keeping on Track	434
15. Marketed Product Monitoring and Post-NDA	445
16. Foreign Guidelines and Registration	447
17. General Comments on Regulations	448
References	448
Guidelines	451
Guidelines Index	479
Author Index	495
Subject Index	507

Overview

1. Historical Background
2. Definitions of Pharmaceutical Stability
3. Some Official Definitions
4. Chemical Stability Versus Kinetics
5. Comments on Physical Plant
6. Sequence of Events

References

An important document in stability testing of pharmaceuticals is the FDA Guideline (which first appeared in 1984, with an updated edition in 1987). This document will be referred to frequently (and it will always be the 1987 edition which is called upon).

There will also be commentary by the author. The opinions and commentary are those of the author, not necessarily those of the Food and Drug Administration (FDA). (They often, hopefully, conform quite well with the FDA's opinion, except on certain points where the author disagrees with the Guidelines.)

First of all the author cannot speak for the FDA. Second, the opinion of the FDA is a somewhat undefined term, since the FDA houses many scientists and, therefore, many opinions. So to speak of the FDA's opinion on a matter is only applicable after the fact, namely whether they accept or reject a certain concept in a new drug application (NDA). Third, the Guidelines are subject to revision from time to time, and commentary that is made today may not apply in a year's time. We now give an overview of what led up to the policies of today.

1. HISTORICAL BACKGROUND

Historically there has always been evidence of concern on the part of the pharmaceutical practitioner and the pharmacist that the drug in the developing or dispensed dosage form be stable. Early incompatibilities (e.g., aspirin and magnesium stearate) were quite obvious from the odor (acetic acid) of the tablets. Quantitization was another matter, since in the first half of this century quantitative assays to detect such problems relied on some color reaction and a colorimeter (not necessarily wavelength specific) for quantitation. (Spectrophotometers, for all practical purposes, were not easily accessible until the late 1940s.)

The introduction of the spectrophotometer on a commercial scale was a giant step forward, yet, since many chromophores are common in both parent and decomposition product, specificity was still lacking. In the 1950s and 1960s such specificity was supplied in a semi-quantitative manner by thin-layer chromatography (TLC), since quite good separations could usually be achieved by this method. Attempts at quantitating TLC were many, but they never really gained a foothold. Instead, high-precision liquid chromatography (HPLC) proved to be the sensor of small amounts of impurity and decomposition product.

There is no doubt that products produced prior to 1950 often were quite unstable, yet assays (nonspecific) would not reveal such instabilities. Solutions (e.g., of procaine hydrochloride) would darken, yet the titrimetric assay would not detect the hydrolysis of the ester group. On the other hand, some of the products at the time (e.g., the sulfonamides) were remarkably stable. Others were not. The best assay for specificity in those years were biological or microbiological assays (vitamin D, penicillins, and, later, tetracyclines). The substances known to be unstable were penicillins, aspirin, and some of the vitamins (vitamin A, thiamine hydrochloride, and ascorbic acid, for instance).

To improve the stability of such compounds, it was desirable to "speed up" the decomposition by some means of stress, and the custom in those days was to consider five weeks at 42°C as equivalent to two years at room temperature. This test had its roots in an article which appeared in Drug and Cosmetic Industry in 1948, espousing (correctly) that five weeks storage of vitamin A at 42°C brought about the same amount of decomposition as vitamin A stored for two years at room temperature. What was forgotten was that this only applies to substances with the same activation energy as vitamin A, and hence general adherence should not be expected. E. R. Garrett (1955) was greatly instrumental in the general understanding of the possibilities and limitations of accelerated testing.

For NDAs in the early years, stability reporting was meager, at times nonexistent, and it was not until the 1960s that there were